Gland Pharma Ltd (GLAND)
₹2,379.80
Mkt cap
₹39,257 Cr
P/E ratio
37.60
P/B
3.78
Div yield
0.84%
ROE
10.70%
ROCE
15.10%
EPS (TTM)
₹63.29
Book value
₹629
52W range
1,597–2,550
Sector
Healthcare
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−6.67% from high₹2,380
₹1,597+49.04% from low₹2,550
Current
₹2,379.80
Prev close
₹2,388.00
Day
−0.34%
Price performance
1D
−0.34%
1W
−3.22%
1M
+2.81%
3M
+38.89%
6M
+42.60%
1Y
+18.53%
YTD
+38.70%
Financials
FRevenue, profit & margin
P/E ratio
37.6×
GLAND is 10% above the sector median of 34.0×
GLAND37.6×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 785 | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | |
| Expenses | 617 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | |
| Operating Profit | 168 | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | |
| OPM % | 21% | 24% | 24% | 23% | 23% | 19% | 21% | 26% | 24% | 24% | 21% | 26% | 29% | |
| Other Income | -18 | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | |
| Interest | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | |
| Depreciation | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | |
| Profit before tax | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | |
| Tax % | 29% | 26% | 33% | 32% | 35% | 34% | 36% | 32% | 35% | 31% | 35% | 28% | 28% | |
| Net Profit | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | |
| EPS in Rs | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.90% · closed higher next day 9 of last 18
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Aug '23◦ | 6 Nov '23◦ | 14 Feb '24◦ | 22 May '24◦ | 6 Aug '24◦ | 4 Nov '24◦ | 3 Feb '25◦ | 20 May '25◦ | 5 Aug '25◦ | 3 Nov '25◦ | 28 Jan '26◦ | 15 May '26◦ |
| Earnings day | +20.00% | +4.97% | −2.72% | +4.95% | −3.75% | +13.78% | −3.66% | +4.87% | −0.37% | −3.05% | +6.53% | +15.43% |
| +1 day | +24.51% | +3.20% | +2.62% | +5.18% | −3.77% | +15.24% | −1.10% | +3.22% | −0.35% | −3.72% | +9.29% | +20.49% |
| +5 days | +15.17% | +2.66% | −2.64% | +3.19% | −7.06% | +9.54% | −4.11% | +1.83% | −0.74% | −6.80% | +9.44% | +24.92% |
| +15 days | +18.83% | +12.69% | −9.48% | +3.50% | −12.24% | +6.67% | +5.55% | +12.25% | −4.74% | −8.94% | +8.92% | +22.49% |
| +30 days | +26.24% | +14.84% | −8.27% | +2.60% | −14.09% | +10.35% | +5.13% | +24.59% | +2.96% | −16.19% | −3.73% | +31.95% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 20 Per Sh | 20.00 | 11 Aug '26 | 11 Aug '26 |
Shareholding
Sas of Jun 202651.77%Promoter
Promoters51.77%0.06
FIIs8.74%1.45
DIIs30.44%2.92
Public9.06%1.54
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Gland Pharma | ₹2,379.80 | 37.60 | 39,257 | 0.84% | 367 | +96.57% | 1,743 | +22.31% | 15.14% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports5
Concall transcripts54
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptMay 2024
Credit ratings4
Announcements5
Board Meeting Intimation for Declaration Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2026 5h - Board meets August 10, 2026 to approve Q1 FY27 results; earnings call at 18:30 IST.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5hShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 20 Jul - Shareholders passed five postal ballot resolutions, including two independent director appointments on July 20, 2026.Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 20 Jul - Postal ballot results on July 20, 2026 approved five director-related resolutions.Announcement under Regulation 30 (LODR)-Change in Directorate 20 Jul - Shareholders approved reappointment of Udo J. Vetter and appointment of William Robert Keller as independent directors.